Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions
ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Moffitt Cancer Center-International Plaza Tampa, Florida, United States
View all 33 locations
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

NCT04263480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Uniklinikum Salzburg Salzburg, Austria
  • Medizinische Universität Wien Vienna, Austria
  • Vivantes Klinikum am Urban Berlin, Germany
  • Ev. Diakoniekrankenhaus Bremen, Germany
View all 17 locations
View Trial Details
Active, Not Recruiting

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348

Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Diseases, Cardiovascular Diseases, +13 more
Locations
  • Research Site Denver, Colorado, United States
  • Research Site Ann Arbor, Michigan, United States
  • Research Site Rochester, Minnesota, United States
  • Research Site Albuquerque, New Mexico, United States
View all 50 locations
View Trial Details
Active, Not Recruiting

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

NCT03286634

Conditions
Abnormalities, Multiple, Acute Lymphoblastic Leukemia, Childhood Cancer, +20 more
Locations
  • Prince of Wales Hospital Shatin, New Territories, Hong Kong
  • Kagoshima University Hospital Kagoshima, Japan
  • University of Malaya Medical Centre Kuala Lumpur, Malaysia
  • Subang Jaya Medical Centre Subang Jaya, Malaysia
View Trial Details
Active, Not Recruiting

Ibrutinib + Venetoclax in Untreated WM

NCT04273139

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Hospital Germans Trias i Pujol (ICO BADALONA) Badalona, Spain
  • Hospital Clinic Barcelona, Spain
  • ICO Duran i Reynals L'Hospitalet de Llobregat, Spain
  • H. Gregorio Marañón Madrid, Spain
View all 15 locations
View Trial Details
Active, Not Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224

Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL), Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Hospital Aleman Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Hospital Britanico de Buenos Aires Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Instituto Alexander Fleming Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
  • Fundaleu - Fundacion Para Combatir La Leucemia Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
View all 81 locations
View Trial Details
Active, Not Recruiting

A Rollover Study of CC-122

NCT05688475

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +27 more
Locations
  • Local Institution - 100 New York, United States
  • Local Institution - 101 Nashville, Tennessee, United States
  • Local Institution - 102 Madison, Wisconsin, United States
  • Local Institution - 300 Bordeaux, France
View Trial Details

Related conditions